Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PIK3CA Mutational Status Assessment: Towards a "Tailored" Diagnostic Approach

NCT06706570 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT06706570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06706570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PIK3CA Mutational Status Assessment: Towards a "Tailored" Diagnostic Approach
Lead sponsor
European Institute of Oncology
Phase
Observational
Overall status
Recruiting
Start date
November 6, 2024
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic